QUARTIER, Pierre, ABRAMS, Ken, HUFNAGEL, Markus, KUBICKI, Rouven, KIRSCHNER, Janbernd, Janda Ales̆, EMERICH, Cornelia und THE PAEDIATRIC RHEUMATOLOGY INTERNATIONAL TRIALS ORGANISATION AND THE PEDIATRIC RHEUMATOLOGY COLLABORATIVE STUDY GROUP, 2021. Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb/IV open‐label, randomized study. Freiburg: Universität.
Elsevier - Harvard (with titles)Quartier, P., Abrams, K., Hufnagel, M., Kubicki, R., Kirschner, J., Janda, A., Emerich, C., The Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group, 2021. Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb/IV open‐label, randomized study. Universität, Freiburg. https://doi.org/10.1002/art.41488
American Psychological Association 7th editionQuartier, P., Abrams, K., Hufnagel, M., Kubicki, R., Kirschner, J., Janda, A., Emerich, C., & The Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. (ca. 2021). Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb/IV open‐label, randomized study [Cd]. Universität. https://doi.org/10.1002/art.41488
Springer - Basic (author-date)Quartier P, Abrams K, Hufnagel M, Kubicki R, Kirschner J, Janda A, Emerich C, The Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group (2021) Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb/IV open‐label, randomized study. Universität, Freiburg
Juristische Zitierweise (Stüber) (Deutsch)Quartier, Pierre/ Abrams, Ken/ Hufnagel, Markus/ Kubicki, Rouven/ Kirschner, Janbernd/ Janda Ales̆/ Emerich, Cornelia/ The Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group, Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb/IV open‐label, randomized study, Freiburg 2021.